Dermapharm Holding (DMPD) Stock Overview
Manufactures and sells off-patent branded pharmaceutical products in Germany, Italy, France, Austria, Switzerland, Spain, Portugal, the Netherlands, Croatia, Poland, Ukraine, the United States, and China. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 2/6 |
DMPD Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Dermapharm Holding SE Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €46.18 |
| 52 Week High | €46.18 |
| 52 Week Low | €38.50 |
| Beta | 0.86 |
| 1 Month Change | 0% |
| 3 Month Change | 19.94% |
| 1 Year Change | n/a |
| 3 Year Change | 1.00% |
| 5 Year Change | -33.75% |
| Change since IPO | 64.53% |
Recent News & Updates
Recent updates
Shareholder Returns
| DMPD | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 0% | 1.6% | 1.5% |
| 1Y | n/a | 25.2% | 19.4% |
Return vs Industry: Insufficient data to determine how DMPD performed against the UK Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how DMPD performed against the UK Market.
Price Volatility
| DMPD volatility | |
|---|---|
| DMPD Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.2% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in GB Market | 12.0% |
| 10% least volatile stocks in GB Market | 3.1% |
Stable Share Price: DMPD's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine DMPD's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 3,503 | Hans-Georg Feldmeier | ir.dermapharm.de |
Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany, Italy, France, Austria, Switzerland, Spain, Portugal, the Netherlands, Croatia, Poland, Ukraine, the United States, and China. The company operates through three segments: Branded Pharmaceuticals; Other Healthcare Products; and Parallel Import Business. It offers branded generics, OTC products, non-prescription healthcare products, and herbal extracts and parallel-imported originator pharmaceuticals.
Dermapharm Holding SE Fundamentals Summary
| DMPD fundamental statistics | |
|---|---|
| Market cap | €2.45b |
| Earnings (TTM) | €144.21m |
| Revenue (TTM) | €1.18b |
Is DMPD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DMPD income statement (TTM) | |
|---|---|
| Revenue | €1.18b |
| Cost of Revenue | €407.97m |
| Gross Profit | €774.27m |
| Other Expenses | €630.06m |
| Earnings | €144.21m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Aug 11, 2026
| Earnings per share (EPS) | 2.91 |
| Gross Margin | 65.49% |
| Net Profit Margin | 12.20% |
| Debt/Equity Ratio | 141.4% |
How did DMPD perform over the long term?
See historical performance and comparisonDividends
Does DMPD pay a reliable dividends?
See DMPD dividend history and benchmarks| Dermapharm Holding dividend dates | |
|---|---|
| Ex Dividend Date | Jun 29 2026 |
| Dividend Pay Date | Jul 01 2026 |
| Days until Ex dividend | 34 days |
| Days until Dividend pay date | 36 days |
Does DMPD pay a reliable dividends?
See DMPD dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/25 14:36 |
| End of Day Share Price | 2026/04/23 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Dermapharm Holding SE is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gerhard Orgonas | Berenberg |
| Fabian Piasta | Jefferies LLC |
| Martin Comtesse | Jefferies LLC |